This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Post-transplant Lymphoproliferative Disorder
Information about Post-transplant Lymphoproliferative Disorder: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Post-transplant Lymphoproliferative Disorder
Most recent studies have shown that Post-transplant Lymphoproliferative Disorder shares some biological mechanisms with b-cell-lymphomas, cytomegalovirus-infections, decreased-immunologic-activity-[pe], diffuse-large-b-cell-lymphoma, epstein-barr-virus-infections, graft-vs-host-disease, herpesviridae-infections, hodgkin-disease, hyperplasia, infective-disorder, lymphoma, lymphoma-non-hodgkin, lymphoproliferative-disorders, malignant-neoplasms, malignant-paraganglionic-neoplasm, neoplasms, polymorphic-post-transplant-lymphoproliferative-disorder, tumor-virus-infections, virus-diseases.
Among the many pathways, these few ones have gauged particular interests from scientists studying Post-transplant Lymphoproliferative Disorder, and have been seen in publications frequently: Anaphylaxis, B Cell Differentiation, B Cell Proliferation, Cell Cycle, Cell Differentiation, Cell Proliferation, Dna Amplification, Glomerular Filtration, Immune Response, Localization, Lymphocyte Activation, Lymphocyte Proliferation, Mismatch Repair, Oncogenesis, Pathogenesis, Regeneration, Secretion, Viral Latency, Viral Replication
Quite a number of genes have been found to play important roles in Post-transplant Lymphoproliferative Disorder, such as BCL2, BCL6, CD4, CD8A, CTLA4, DDIT3, HLA-DQA1, IFNG, IL10, IL2, IL6, KRT20, MS4A1, MYC, NOD2, PDLIM7, SDC1, TNF, TNFRSF8. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.